Soterix Medical

Focus: Soterix Medical is a neuromodulation-focused biotech company specializing in transcranial stimulation technologies for neurological and psychiatric disorders. Founded in 2008 and headquartered in Woodbridge, NJ, the company operates as a public-stage enterprise with a portfolio spanning depression, aphasia, cognitive impairment, and substance use disorders.

Neurology Neurological and psychiatric disorders

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Soterix Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Soterix Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

15 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Transcranial Magnetic Stimulation

Treatment Resistant Depression

N/A

Clinical Trials (1)

NCT05598931Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

N/A

Help build intelligence for Soterix Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering neuromodulation platform with diversified pipeline across 15 active trials spanning depression, aphasia, cognitive impairment, and addiction — offering breadth in neuropsych indication exposure
Dual clinical-stage programs (Phase 2 HD-tDCS for aphasia, Phase 2 accelerated rTMS for TRD) provide near-term clinical catalysts and learning opportunities
Device-based modality differentiates from crowded pharma landscape; tDCS/rTMS represent white space in neuromodulation with growing clinical validation

Watch Out For

Only 1 active job posting signals minimal near-term hiring and potential resource constraints or organizational maturity challenges
No Phase 3 programs in pipeline and limited financial/revenue data suggests early-stage cash demands and unproven commercial viability
Zero peer-reviewed publications on record raises questions about scientific rigor, IP strength, and ability to attract top-tier talent

Generated by Claude from Soterix Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

transcranial direct current stimulation

Unipolar Depression

N/A

Clinical Trials (1)

NCT07042217Transcranial Direct Current Stimulation for Depression

N/A

Soterix Medical mini-CT tDCS stimulator

Cocaine Use Disorder

N/A

Clinical Trials (1)

NCT03833583TDCS for Cocaine Addiction Craving

N/A